CYTOKINETICS, INCORPORATED Restricted Cash and Cash Equivalents, Noncurrent
CYTOKINETICS, INCORPORATED (CYTK) had Restricted Cash and Cash Equivalents, Noncurrent of $51.00 thousand as of 2012-03-31, per its 10-Q filed 2012-05-04.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:RestrictedCashAndCashEquivalentsNoncurrent · last filed 2013-03-15
- 2012-03-31: Restricted Cash and Cash Equivalents, Noncurrent $51.00K.
- 2011-12-31: Restricted Cash and Cash Equivalents, Noncurrent $196.00K.
- 2011-09-30: Restricted Cash and Cash Equivalents, Noncurrent $215.00K.
- 2011-06-30: Restricted Cash and Cash Equivalents, Noncurrent $439.00K.
| Period end | Restricted Cash and Cash Equivalents, Noncurrent |
|---|---|
| 2012-03-31 | $51.00K 10-Q · filed 2012-05-04 |
| 2011-12-31 | $196.00K 10-K · filed 2013-03-15 |
| 2011-09-30 | $215.00K 10-Q · filed 2011-11-04 |
| 2011-06-30 | $439.00K 10-Q · filed 2011-08-04 |
| 2010-12-31 | $788.00K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |